Navigation Links
Agent in Medical Technology

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

... to evaluate KRX-0401 (perifosine) as a single agent treatment for recurrent solid tumors in pediatric ... KRX-0401 is a novel, oral, anticancer agent that modulates Akt and several other important ... Cancer Institute demonstrated that single agent perifosine not only induced tumor regression and ...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

... obtained the rights to develop and market a novel agent for the prevention and treatment of neuropathies ... CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth factor ... "In preclinical studies, our small molecule agent CXB909 has been shown to increase the action of ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... Regardless of the particular anti-TNF-alpha agent previously used in treatment (adalimumab, ... the efficacy and safety of an anti-TNF-alpha agent in patients previously treated with other ... Reasons for discontinuation of prior anti-TNF agent included lack of efficacy (58 percent), ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

... KRX-0401 Demonstrates Impressive Single agent Efficacy in Patients who Progressed after Failing ... as a secondary endpoint. Best response to single agent perifosine was as follows: Group ... group, best response and median PFS to single agent perifosine was as follows: Group ...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

... to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent in combination with temozolomide (Temodar(R)). ...

ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent

... less toxic and more active than the FDA approved agent ribavirin. Preliminary in vivo toxicology ... "We believe that the addition of a novel agent such as PG301029 to the current standard of care ... based on their transcription targeted therapeutic agent platform. For further information ...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... our belief that ProLindac is an active platinum agent with a favorable side effect profile," stated ... kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to ... ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. Access ...

Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma

... benefit for pixantrone when used as single agent therapy in the treatment of multiple relapsed ... prior therapy with doxorubicin, an agent in a similar class with cumulative ... (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular ...

Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997

... the company's anticancer vascular-disrupting agent (VDA). The primary objectives of this ... and the dose-limiting toxicities (DLTs) for the agent when administered orally in capsule form every ... intravenously. The oral activity of the agent should markedly improve its clinical and ...

Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

... the program. The Altropane molecular imaging agent is being developed by Alseres to aid in the early ... "We believe that Altropane represents an imaging agent that is not only 'first-in-class' in the U.S. ... Altropane Altropane is a molecular imaging agent that specifically binds to the dopamine ...

Access Pharmaceuticals Presents new Combination Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody

... mechanism. Angiolix(R) is a promising novel agent for anti-angiogenic cancer therapy. Angiolix has ... kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to ... ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For ...

Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence

... and efficacy of Macroplastique to another bulking agent used in the control group. In the Macroplastique ... available bioabsorbable urethral bulking agent for one year. Of the 247 study ... Macroplastique(R) Implants, an injectable bulking agent for the treatment of adult female stress urinary ...

FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation

... Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in ... for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing ... LUSEDRA is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... demonstrated that perifosine is an active, novel agent with the potential to provide clinical benefit to ... Macroglobulinemia (WM) Single agent perifosine achieved a 36% ORR (MR, PR) and 58% ... potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... Phase 2 Study of Voreloxin as Single agent Therapy (REVEAL-1 Trial) Interim data from ... E valuation of V or E loxin in A m L ) single agent Phase 2 trial show that voreloxin induces ... Phase 2 portion of this study. Single agent cytarabine is the current treatment standard for ...

Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects

... Receptor Antagonist (TRA), a novel antiplatelet agent that can potentially prevent the formation of ... (golimumab), a once-monthly subcutaneous anti-TNF agent for inflammatory and autoimmune disorders (under ... (asenapine), a novel psychopharmacologic agent (under U.S. review for schizophrenia and acute ...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

... 1 dose escalation trial of voreloxin as a single agent in acute leukemias (N=73) showed that ... The researchers concluded that single agent activity in the relapsed/refractory AML ... voreloxin at a dose of 48 mg/m2 as a single agent once every three weeks. At this dose, ...

PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop

... on the battlefield or civilian victims of nerve agent attacks. Valortim(R), in co-development with ... may have efficacy as a therapeutic against nerve agent exposure. -- A study of Valortim(R) in a ... mimics percutaneous exposure. In this model, free agent was measured in both the dermis and blood ...

Major State Grant Accelerates Research and Development of Novel Cancer Therapy

... developing an over-the-counter skin protective agent with unique antioxidant properties. "SURECAG is ... compound that in combination with an oxidizing agent or agent that generates reactive oxygen species ...

Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy

... of hematological malignancies as both a single agent and in combination with other therapies. This ... with leukemia. Laromustine is a promising agent for that effort." The trial has been designed ... evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de ...

Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma

... causing apoptosis in cancer cells. In single agent Phase 1 studies carfilzomib has demonstrated ... currently evaluating carfilzomib as a single agent for the treatment of multiple myeloma in two ... is evaluating carfilzomib as a single agent in a Phase 2 trial of patients with advanced ...

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

... RCC are warranted either as a single agent or in combination with one of the newer targeted ... antibody, bevacizumab (Avastin). Although each agent can provide some benefit in a subset of patients, ... in multiple tumor types both as a single agent and in combination with other drugs. Agennix ...

Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate

... Champions Biotechnology intends to test the BPU agent utilizing its Biomerk Tumorgraft(TM) Preclinical ... preclinical models. By testing the BPU agent against panels of Biomerk Tumorgrafts from ... M.D., Ph.D. Champions Biotechnology's BPU agent is an antimitotic inhibitor that targets MAPT ...

Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies

... Will Bring Innovative Fluorescent Imaging agent and System Technologies into Clinical ... treatment." The ProSense(R) Activatable Imaging agent platform was developed to provide in vivo ... on the metabolism of the agent to support expanded Phase II clinical trials. ...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

... Data from Phase 1 Single agent and Phase 1b Combination Clinical Trials ... Phase 1 trial of voreloxin when used as a single agent in relapsed or refractory patients with ... with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ...

Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma

... gadolinium has been shown to have single agent activity in lymphoma and is synergistic with ... Pharmacyclics is developing MGd as an anti-cancer agent with a novel mechanism of action that is designed ... non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy ...

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

... phase 2 results demonstrating the single agent clinical activity of perifosine in patients ... MA, discussed the phase 2 results on the single agent clinical activity of perifosine in patients with ... summary, the investigators conclude that single agent perifosine showed encouraging activity with ...

Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients

... of Clolar(R) (clofarabine) as a single agent in previously untreated, older adult patients ... prognostic factors who received single agent clofarabine exhibited a 45 percent overall ... efficacy findings we are observing with single agent clofarabine, we also see impressive responses in ...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

... and preclinical activity of KRX-0401 as a single agent and in combination with novel agents are ... potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key ... variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and ...

Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO

... development of this compound both as a single agent and in combination with other anti-cancer ... Phase 1b/2 clinical trials of XL765 as a single agent and in combination with other targeted agents or ... efficacy in xenograft models, both as a single agent and in combination with other therapies. About ...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine

... I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with ... of these devastating conditions as both a single agent and in combination with other therapies." Dr. ... evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de ...

Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer

... is a new generation platinum chemotherapy agent with the potential to become a platform ... this product." Picoplatin is a chemotherapeutic agent that has an improved safety profile compared to ... position picoplatin as the preferred platinum agent for the first-line treatment of ...

Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program

... patient enrollment. ALTROPANE molecular imaging agent is an investigational, diagnostic drug developed ... nervous system diagnostic molecular imaging agent -- and a valuable tool to help clinicians make ... and their families. About ALTROPANE Imaging agent and Parkinsonian Syndromes Including Parkinson's ...

EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

... substantial, dose-dependent efficacy as a single agent in multiple preclinical models, including tumor ... models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in ... its significant antitumor potential as a single agent in a variety of tumor types. Through this Phase 1 ...

Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure

... placebo. "Debio 0614 is a novel intravenous agent combining inotropic and lusitropic properties. ... a trend to decrease heart rate, that makes this agent a promising therapy for the acute heart failure ... Debio 0614 is a first in class luso-inotropic agent with calcium cycling modulating properties. It ...

FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)

... BFPET is FluoroPharma's second cardiovascular PET agent to enter clinical trials. BFPET is a PET blood ... of 70:1, and we look forward to evaluating the agent in human studies." "We are delighted to have ... progress follows on the tail of CardioPET, an agent for the detection of metabolic integrity of the ...

OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection

... -Provides Additional Evidence That This Phase II agent Has Good Tolerability and Broad Anti-Microbial ... efficacy could make it a potentially valuable new agent for addressing a variety of ocular infections." ... drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III ...

Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)

... with the related drug, mitoxantrone, an agent currently approved to treat severe ... [is] a promising immunosuppressant agent suitable for clinical investigation in myasthenia ... Pixantrone Pixantrone is an investigational agent under development for the potential treatment of ...

Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML

... has recently shown very significant single agent activity in a the difficult to treat elderly AML ... (VNP40101M) is an active agent in AML, and we continue to believe that it will ... and second line settings, as either a single agent or in combination with other therapies." The ...

AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma

... dacarbazine, and the immunotherapy agent interleukin-2. Dacarbazine as a single agent has minimal activity and interleukin 2 is not ... 10 years. In studies of dacarbazine as a single agent to treat malignant melanoma, median ...
Other Contents
(Date:6/16/2015)...  With the increasing number and severity of data ... The recent compromise of Federal employee data from ... within government agencies. HYPR Corp. announced today ... authenticator, has been submitted for testing and approval of ... for tamper proofing. The proliferation of ...
(Date:6/15/2015)... DALLAS , June 16, 2015 ... Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), ... Worldwide Forecast to 2020" published by MarketsandMarkets, The Natural ... Billion at a CAGR of 18.4% for the forecast ... Tables and   46 F igures spread   ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
(Date:6/29/2015)... ... June 29, 2015 , ... National ... auditor of customer service for the 40-center nursing home group. Sixteen of their ... centers in the United States in one or more customer service areas. Those ...
(Date:6/29/2015)... Newark, Delaware (PRWEB) , ... June 29, 2015 , ... ... Exam Master® announces a partnership with the American Board of Urgent Care Medicine and ... AMA PRA Category 1 Credit™ to Urgent Care physicians and health care professionals. , ...
(Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the ... and feel, as well as a redesigned logo and weekly eLetter. The website contains ... now more user-friendly and easier to navigate. , In addition to a refreshed ...
(Date:6/29/2015)... ... June 29, 2015 , ... The Food Safety and ... The Hong Kong Polytechnic University (PolyU) has developed a new method for rapid ... has been a long-term issue in food safety, and becomes particularly important with ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... between personality type and behavior, is a popular focus for corporate training seminars. ... to streamline hiring practices, improve training, foster teamwork, and increase productivity. , ...
Breaking Medicine News(10 mins):Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3Health News:OR Manager Launches New Website 2Health News:PolyU develops a new method for rapid authentication of edible oils and screening of gutter oils 2Health News:As Demand for DISC Trainers Rises, PeopleKeys Offers Support with “THE DISC FACTOR—Train the Trainer” Webinar 2
Other TagsOther Tags